<?xml version="1.0"?>
<rdf:RDF xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:dc="http://purl.org/dc/elements/1.1/"><rdf:Description rdf:about="https://dirros.openscience.si/IzpisGradiva.php?id=18424"><dc:title>Genetic markers in oligodendroglial tumours</dc:title><dc:creator>Velnar,	Tomaž	(Avtor)
	</dc:creator><dc:creator>Smrdel,	Uroš	(Avtor)
	</dc:creator><dc:creator>Popović,	Mara	(Avtor)
	</dc:creator><dc:creator>Bunc,	Gorazd	(Avtor)
	</dc:creator><dc:description>Background. Oliogodendrogliomas are brain tumours composed of the cells resembling oligodendrocytes. They represent the third most common glial tumour, comprising 2.5% of all primary brain tumours and 5-20% of all gliomas. Conclusions. Oligodendroglial tumours with 1p and 19q loss demonstrate a better overall prognosis due to more indolent clinical behaviour and higher sensitivity to treatment. Additionally, 1p and 19q loss is a marker of clinical utility, helping to assess tumour sensitivity to chemotherapy and harbouring the potential for improving the diagnosis and survival of oligodendroglioma patients as well as future clinical practice.</dc:description><dc:publisher>Association of Radiology and Oncology</dc:publisher><dc:date>2010</dc:date><dc:date>2024-03-15 13:41:52</dc:date><dc:type>Neznano</dc:type><dc:identifier>18424</dc:identifier><dc:source>Ljubljana</dc:source><dc:language>sl</dc:language><dc:rights>by Authors</dc:rights></rdf:Description></rdf:RDF>
